SAN DIEGO--(BUSINESS WIRE)--MicroIslet Inc., (OTCBB: MIIS, http://www.microislet.com), a biotechnology company engaged in the development and commercialization of cell transplantation therapies for diabetes, today announced the formation of a new Scientific Advisory Board. The Company named John B. Buse, M.D., Ph.D., David W. Scharp, M.D., Christopher L. Marsh, M.D., F.A.C.S, Bassam Damaj, Ph.D., Miguel Carlos Riella, M.D., Ph.D., and John Logan, Ph.D. as members. The new Scientific Advisory Board will assist MicroIslet in the development of its MicroIslet-PTM product for the treatment of type 1 diabetes.
